Vous trouverez d'autres informations au laser 2RT d'Ellex
sur notre PAGE DE PRODUITS
The LEAD multi-center trial1 has shown that 2RT® Retinal Rejuvenation achieves a 77% reduction in the rate of progression to late stage AMD for over three quarters of early stage AMD patients, according to a post hoc analysis.2
77% reduction in the rate of progression to late-stage AMD in 76% of suitable patients who received 2RT® over the 36 months of the LEAD trial.
1 Guymer RH, Wu Z, Hodgson LAB, et al. Sub-Threshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial. Ophthalmology. 2018. 2 Post hoc analysis in patients without coexistent reticular pseudodrusen (RPD).
Retinal Rejuvenation Therapy, 2RT®, stimulates a biological healing process that results in cellular rejuvenation, renewing the entire transport mechanism of the retina and improving the hydraulic conductivity of Bruch’s membrane. This rejuvenation process preserves or improves functional vision and reduces disease progression — without causing collateral damage to the overlying photoreceptor rods and cones of the retina. 2RT® offers the potential to intervene earlier in the treatment of AMD before significant vision loss has occurred to slow or halt the degeneration process.
Ellex is the manufacturer of 2RT®. It has been approved for the indications Clinically Significant Macular Edema (CSME) and in patients with early Age-Related Macular Degeneration (AMD) where it can produce bilateral improvements in macular appearance and function under CE marking. Ellex does not accept any responsibility for use of the system outside of these indications. The material presented herein may include the views or recommendations of third parties and does not necessarily reflect the views of Ellex Medical Pty Ltd.
2RT® has a CE Mark (Conformité Européene) for treatment in patients with early AMD where it can produce bilateral improvements in macular appearance and function.
2RT® has a CE Mark (Conformité Européene) and US Food and Drug Administration (FDA) (510k) Market release for the treatment of Clinically Significant Macular Edema (CSME).
2RT® is not approved for sale in the USA for the indication of early AMD.